Mpox Update: Clinical Management and Outbreaks

At a glance

During this COCA call, presenters will give updates on the clade I outbreak in DRC and remind clinicians to be alert for cases of mpox in patients with recent travel to DRC.

Webinar

View Slides
View Transcript

Free Continuing Education

Overview

The Centers for Disease Control and Prevention has been supporting the Democratic Republic of the Congo (DRC) in responding to its largest surge of clade I mpox (MPVX) cases ever recorded. Since January 1, 2023, DRC has reported more than 20,000 suspect mpox cases and more than 1,000 deaths. Clade IIb mpox continues to circulate in the United States but at much lower levels. The 2022 global clade IIb mpox outbreak caused more than 97,000 illnesses around the world, including more than 32,000 cases and 58 deaths in the United States.

During this COCA call, presenters will give updates on the clade I outbreak in DRC and remind clinicians to be alert for cases of mpox in patients with recent travel to DRC. Presenters will discuss when to suspect a case of mpox, provide updates on the clinical management and prevention of clade II mpox, discuss the epidemiology of clade II mpox, and cite vaccination data. They will also discuss the commercialization of the JYNNEOS vaccine and outline the update to the expanded access Investigational New Drug (EA-IND) for Tecovirimat (TPOXX).

Presenters

Agam Rao, MD
CAPT, U.S. Public Health Service
Chief Medical Officer for the Poxvirus and Rabies Branch
Division of High-Consequence Pathogens and Pathology
Centers for Disease Control and Prevention

Meghan Pennini, PhD
Chief Science Officer
HHS Coordination Operations and Response Element
Administration for Strategic Preparedness and Response
U.S. Department of Health and Human Services

Yon Yu, PharmD
CAPT, U.S. Public Health Service
Lead, Medical Countermeasures Regulatory Support Team
Office of Readiness and Response
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC's role in the topic covered during the presentation.
  3. Describe the topic's implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives

  1. Discuss the epidemiology of clade II MPXV and U.S. clinical and vaccine.
  2. Describe the JYNNEOS vaccine commercialization.
  3. Explain TPOXX EA-IND eligibility criteria for treating mpox.

Additional Resources

Continuing Education

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for WC4520R-062724—Mpox Update: Clinical Management and Outbreaks, please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-062724. Follow the steps below by July 29, 2024. The registration code is COCA062724.

To receive continuing education (CE) for WD4520R-062724—Mpox Update: Clinical Management and Outbreaks, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-062724. Follow the steps below between July 30, 2024, and July 30, 2026.

  1. Register for and complete the course.
  2. Pass the post-assessment at 75%.
  3. Complete the evaluation.
  4. Visit Your Learning to access your certificates and transcript.

Accreditation Statements

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Jointly Accredited Provider logo
CDC is a Jointly Accredited Provider in Interprofessional Continuing Education.

CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: Credit Designation Statement – Live
The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-24-088-L04-P and enduring JA4008229-0000-24-089-H04-P.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEUs for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Megan Pennini who will discuss using Jynneos for populations who are currently covered under EAU but not on the approved label; and Dr. Yon Yu who will provide an update on the eligibility criteria for using tecovirimat for treating Mpox, which is an unapproved (investigational) use of an approved drug only available in the United States through the USG stockpile.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Target Audience

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians

Additional Information

  • Contact Information: coca@cdc.gov
  • Support/Funding: Centers for Disease Control and Prevention, Office of Emergency Risk Communication
  • Method of Participation: You may participate in the educational activity by viewing the program information above.
Print
Content Source: